MedImmune Social Media Press Room

GAITHERSBURG, Md., Aug. 10 /PRNewswire/ — MedImmune today announced that it has advanced three oncology antibody programs into Phase 1 clinical development within the past six months. All three of the antibody candidates will target a variety of advanced solid tumors, but via different pathways.

“Cancer research has long been a priority focus area at MedImmune and we are proud of the organization’s hard work to achieve first-time-in-human-status for all three candidates,” said Laurence Moore, M.D., Ph.D., vice president, clinical development, oncology. “We look forward to continuing to evaluate how managing the various biological targets inherent in these very different antibodies may potentially lead to better health outcomes for patients suffering from a myriad of cancers.”

• MEDI-573: is a fully human antibody that selectively binds to
  insulin-like growth factors (IGFs) I and II and inhibits IGF I and II
  mediated signal transduction in tumor cells; thus this antibody could
  potentially inhibit tumor growth.
• MEDI-575: is a fully human antibody targeting the platelet-derived
  growth factor-receptor (PDGF receptor) subunit, which is thought to play an
  important role in human cancers, both as a direct target on tumor
  cells and as a mediator of stromal support for cancer cell growth.
  The interaction between stromal cells and tumor cells is known to play
  a major role in cancer growth and progression; therefore, blocking
  PDGF alpha with an effective antibody could potentially reduce the
  growth and metastases of solid tumors.
• MEDI-547, an antibody-drug conjugate, is a fully human monoclonal
  antibody designed to target the over expression of the EphA2 protein
  linked to a potent drug payload. Cumulative evidence suggests a
  correlation between EphA2 over-expression and clinical features of
  aggressive cancer. MEDI-547 is a result of MedImmune scientists
  utilizing technology licensed from Seattle Genetics.

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune’s website at www.medimmune.com.